Cargando…

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined

Detalles Bibliográficos
Autores principales:	Chouaïd, Christos, Baize, Nathalie, Monnet, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653159/ https://www.ncbi.nlm.nih.gov/pubmed/33209596 http://dx.doi.org/10.21037/tlcr-20-362

Ejemplares similares

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study
por: Gibiot, Quentin, et al.
Publicado: (2020)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

The memory remains
por: Altmeyer, Matthias
Publicado: (2018)

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
por: Chouaid, Christos, et al.
Publicado: (2022)

Recent Advances and Remaining Challenges in the Management of Diabetic Kidney Disease
por: Gervasini, Guillermo
Publicado: (2023)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019
por: Steiner, T. J., et al.
Publicado: (2020)

Cost analysis of adverse events associated with non-small cell lung cancer management in France
por: Chouaid, Christos, et al.
Publicado: (2017)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
por: Vergnenègre, Alain, et al.
Publicado: (2012)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
por: Taipale, Kaisa, et al.
Publicado: (2017)

Second-line treatment for renal cell cancer
por: Di Lorenzo, G, et al.
Publicado: (2012)

Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience
por: Habib, Emmad E., et al.
Publicado: (2012)

Invasive Candidiasis in Children: Challenges Remain
por: Baalaaji, Mullai
Publicado: (2022)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Optimizing the management of lung cancer: Role of the pulmonologist in India
por: Mohapatra, Prasanta R.
Publicado: (2013)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

Perspective of pharmaceutical sciences in Iran; Jobs remaining
por: Abdollahi, M.
Publicado: (2011)

Breast screening remains a controversial issue
por: Harris, A L
Publicado: (2013)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
por: Lazzari, Chiara, et al.
Publicado: (2017)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Leprosy: making good progress but hidden challenges remain
por: Smith, W. Cairns S.
Publicado: (2013)

HIV prevention & treatment - Reasons to rejoice & remain vigilant
por: Excler, Jean-Louis
Publicado: (2015)

The risk of stent thrombosis is multifactorial and may remain for long
por: Shite, Junya
Publicado: (2013)

Health and medical research for all: The challenge remains open
Publicado: (2019)

And once the storm is over… ICM will remain the intensivist’s beacon
por: Citerio, Giuseppe
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pld4r6t7ms2p3989fmr45vot6a